Postmenopausal Women With ER+ HER2- Primary Breast Cancer
1 clinical trials · Condition
◉ Watch Postmenopausal Women With ER+ HER2- Primary Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer. (NCT03236974) | AstraZeneca | 2017-10-05 |
Track Postmenopausal Women With ER+ HER2- Primary Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.